Kyle Musgrove, Richard Ripley, Sep 30, 2013
Three months now have passed following the Supreme Court’s decision inFTC v. Actavis, 133 S. Ct. 2223 (2013), which subjects to “rule of reason” antitrust scrutiny certain pharmaceutical patent settlements involving a cash payment by the branded drug company to the generic drug company. With the benefit of time and hindsight we can say two things are certain: First, litigants and courts are struggling to construct a framework to imple
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.222.131.239
Please verify email or join us to access premium content!